ADVFN US – Market Content Editor
-
Gold Rebounds Toward $4,350 as Markets Await US CPI Data
Gold prices recovered on Friday after declining nearly 2% in the previous session, as investors assessed the outlook for US interest rates ahead of August consumer inflation data. At 01:59 ET (05:59 GMT), spot gold rose 0.8% to $4,351.28 an ounce, while gold futures declined 0.4% to $4,391.37. Spot silver gained 0.8% to $64.10 an…
-
Oil Heads for Weekly Close Above $100 as US Diesel Reaches Record High
Oil prices declined on Friday but remained on course to finish the week above $100 per barrel for the first time since mid-May, while the US national average diesel price reached a record high amid disruptions to energy supplies and shipping routes. Brent crude futures fell $1.65, or 1.53%, to $105.98 per barrel by 07:58…
-
US Stock Futures Rise Ahead of CPI as Oracle and Adobe Report Results: Dow Jones, S&P, Nasdaq, Wall Street
US stock futures moved higher on Friday as investors awaited August consumer inflation data ahead of the Federal Reserve’s interest-rate decision next week. At 02:57 ET (06:57 GMT), Dow futures were up 232 points, or 0.5%, while S&P 500 futures gained 33 points, or 0.4%. Nasdaq 100 futures advanced 120 points, also up 0.4%. The…
-
Oil Above $100 Sends Stocks to a Fourth Straight Loss as Yields Surge
U.S. stocks fell for a fourth consecutive session on Thursday as a sharp spike in oil prices reignited inflation worries and pushed Treasury yields to multi-year highs. West Texas Intermediate crude closed above $100 a barrel for the first time in months, and the jump rippled across the market, squeezing corporate margins and raising the…
-
American Fusion Highlights Texatron Testing as It Targets AI and Data Center Power Market
American Fusion says its Texatron program is targeting unity or beyond-unity testing by the end of 2026, while prospective commercial opportunities remain dependent on successful validation. Key Investor Takeaways Why AMFN Stock Is in Focus American Fusion provided additional details about its Texatron testing and commercialization strategy through an interview with Executive Chairman Brent Nelson.…
-
Black Dragon Resource Announces Funding Commitment for Share Retirement and Sand Plant Acquisition
Black Dragon Resource says its chairman and CEO is committing funds without convertible notes or toxic investments as the company targets share retirement, an acquisition and an upgrade to a higher trading tier. Key Investor Takeaways Why BDGR Stock Is in Focus Black Dragon Resource announced a financial commitment from its chairman and CEO aimed…
-
AeroVironment Secures First International LOCUST Counter-Drone System Order Worth More Than $50 Million
The first overseas purchase of AeroVironment’s LOCUST laser weapon system expands the directed energy platform beyond its U.S. deployments and follows a $464.8 million U.S. Army contract. Key Investor Takeaways Why AVAV Stock Is in Focus AeroVironment has secured its first international LOCUST counter-drone system order, moving the high-energy laser platform into an overseas commercial…
-
Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study
The completed SKNJCT-003 study is shaping Medicus Pharma’s next clinical strategy, with the 200 µg dose moving into an FDA-authorized Gorlin syndrome program while the company considers partnerships for nodular basal cell carcinoma. Key Investor Takeaways Why MDCX Stock Is in Focus Medicus Pharma has published an abridged final Clinical Study Report for its Phase…
-
1-800-FLOWERS.COM Reports Revenue Decline as Company Evaluates Capital Raising Options
Fiscal 2026 revenue fell 10.8% to $1.50 billion and adjusted EBITDA declined to $2.9 million, while the company amended its credit agreement and began reviewing financing and asset-sale alternatives. Key Investor Takeaways Why FLWS Stock Is in Focus 1-800-FLOWERS.COM reported lower fiscal 2026 revenue and adjusted profitability while outlining measures intended to provide additional financial…
-
Roche’s Genentech Gets FDA Priority Review for Enspryng in MOGAD
The FDA is expected to decide by January 10, 2027, after a Phase III study showed Enspryng reduced the risk of MOGAD relapse by 68% versus placebo. Key Investor Takeaways Why RHHBY Stock Is in Focus The FDA granted Priority Review to Genentech’s application seeking to expand Enspryng into myelin oligodendrocyte glycoprotein antibody-associated disease, or…